Healthcare Industry News:  Hi-Art System 

Devices Oncology

 News Release - October 17, 2007

TomoTherapy Incorporated and IBA Dosimetry to Showcase Helical Dosimetry(R) Solution at ASTRO 2007

MADISON, Wis.--(HSMN NewsFeed)--TomoTherapy Incorporated (NASDAQ:TTPY ) announced today a strategic alliance with IBA Dosimetry to provide Helical Dosimetry®, a suite of quality assurance products for the TomoTherapy® Hi-Art® treatment system. The products, to be showcased at ASTRO's 49th Annual Meeting in Los Angeles, will facilitate fast, accurate digital verification of TomoTherapy's 360-degree intensity-modulated radiation therapy (IMRT) treatment plans.

"We're excited to partner with IBA Dosimetry," stated Corey Lawson, director of product strategy for TomoTherapy. "As more and more treatment centers move to our innovative platform for helical IMRT, it is critical that we provide options for, and access to, equally innovative quality assurance solutions. This alliance gives us that capability."

The Helical Dosimetry package includes the I'mRT MatriXX, for verification of absorbed dose compared to planned dose, and the MatriXX Multi-Cube phantom for quality assurance.

"In both delivery method and integration, the Hi-Art System represents an exciting and innovative direction for radiation therapy," said Chuck Lindley, president of IBA Dosimetry in North America. "We are delighted to provide TomoTherapy users worldwide with tools to further enhance their clinical workflow efficiency."

About IBA

IBA delivers solutions of exceptional precision in the fields of cancer diagnosis and therapy. The company also provides sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment, and belongs to the BelMid index. Web site: www.iba-worldwide.com

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, manufactures and sells the TomoTherapy® Hi-Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi-Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company completed its initial public offering in May 2007 and its stock is traded on the NASDAQ Global Market under the symbol TTPY. To learn more about TomoTherapy, please visit our Web site at www.TomoTherapy.com.

Forward-Looking Statements

Statements in this release regarding future products, events, expectations and other similar matters, including but not limited to statements using the terms "will" or "can" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to risks inherent in the development and commercialization of new technology and products, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of this date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.

©2007 TomoTherapy Incorporated. All rights reserved. TomoTherapy, the TomoTherapy logo and Hi-Art and CTrue are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.


Source: TomoTherapy

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.